References
- 1. PLUMADORE E, LOMBARDO L, AND CABRAL KP. Pharmacotherapy review: Emerging treatment modalities in transthyretin cardiac amyloidosis. Am J health-Syst Pharm. 2022; 79:52–62.
- 2. PERFETTO F, ZAMPLERI M, FUMAGALLI C, ALLINOVI M, CAPPELLI F. Circulating biomarkers in diagnosis and management of cardiac amyloidosis: a review for internist. Internal and Emergency Medicine. 2022; 17:957–969.
- 3. YAMAMOTO H, YOKOCHI T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Failure. 2019; 6:1128–1139.
- 4. GILLMORE JD, REILLEY MM, COATS CJ, COOPER R, COX H, COYNE MR, et al. Clinical and genetic evaluation of people with or without risk of hereditary ATTR amyloidosis: An expert opinion and consensus on best practice in Ireland and the UK. Adv Ther. 2022; 39:2292–2301.
- 5. JAIN A, ZAHRA F. Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Treasure Island, 2022. PMID 34662045.
- 6. ANDO Y, ADAMS D, BENSON MD, BERK JL, PLANTE-BORDENEUVE V, COELHO T, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;1–13.
- 7. OBI CA, MOSTERTZ WC, GRIFFIN JM, JUDGE DP. ATTR epidemiology, genetics, and prognostic factors. Methodist DeBakey Cardiovasc J. 2022;18(2):17–26.
- 8. RIMBAS RC, BALINISTEANU A, MAGDA SL, VISOIU SI, CIOBANU AO, BEGANU E, et al. New advanced imaging parameters and biomarkers – a step forward in the diagnosis and prognosis of TTR cardiomyopathy. J Clin Med. 2022;11(2360):1–26.
- 9. GROGAN M, SCOTT CG, KYLE RA, ZELDENRUST ST, GERTZ MA, LIN G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014–20.
- 10. DONNELLAN E, WAZNI OM, SALIBA WI, BARANOSWKI B, HANNA M, MARTYN M, et al. Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol. 2019;30(11):2427–2432.
- 11. GILLMORE JD, DAMY T, FONTANA M, HUTCHINSON M, LACHMANN HJ, MARTINEZ-NAHARRO A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799–2806.
- 12. OBICI L, BERK JL, GONZÁLEZ-DUARTE A, COELHO T, GILLMORE J, SCHMID HH, et al. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid. 2020;27(3):153–162.
- 13. STERN LK, PATEL J. Cardiac amyloidosis treatment. Methodist DeBakey Cardiovasc J. 2022;18(2):59–72.
- 14. TSCHOPE C, ELSANHOURY A. Treatment of transthyretin amyloid cardiomyopathy: The current options, the future, and the challenges. J Clin Med. 2022;11(2148):1–14.
- 15. KAMDAR F, TAN CM, RODRIGUEZ ER, MOAZAMI N, HANNA M. Intramural coronary light-chain amyloidosis and left ventricular assist device implantation. The Journal of Heart and Lung Transplantation. 2020;39(10):1163–1164.
- 16. Vyndaqel, Package insert. Pfizer Labs: 2020.
- 17. Vyndamax, Package insert. Pfizer Labs: 2020.
- 18. COELHO T, MAIA LF, MARTINS DA SILVA A, WADDINGTON CRUZ M, PLANTE-BORDENEUVE A, LOZERON P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785–792.
- 19. MAURER MS, SCHWARTZ JH, GUNDAPANENI B, ELLIOTT PM, MERLINI G, WADDINGTON-CRUZ M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007–1016.
- 20. BERK JL, DYCK PJ, OBICI L, ZELDENRUST SR, SEKIJIMA Y, YAMASHITA T, et al. The diflunisal trial: update on study drug tolerance and disease progression. Amyloid. 2011; 18(sup1):196–192.
- 21. ADAMS D, GONZALEX-DUART A, O’RIORDAN WD, YANG CC, UEDA M, KRISTEN AV, et al. Patisiran, an RNAi therapeutic, for hereditarytransthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
- 22. HABTEMARIAM BA, KARSTEN V, ATTARWALA H, GOEL V, MELCH M, CLAUSEN VA, et al. Single-dose pharmacokinetics and pharmacodynamics of transthyretin targeting n-acetylgalactosamine-small interfering ribonucleic acid conjugate, vutrisiran, in healthy subjects. Clin Pharmacol Ther. 2021;109(2):372–382.
- 23. BENSON MD, WADDINGTON-CRUZ M, BERK JL, POLYDEFKIS M, DYCK PJ, WANG AK, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 Jul 5;379(1):22–31. doi: 10.1056/NEJMoa1716793.
- 24. JUDGE DP, HEITNER SB, FALK RH, MAURER MS, SHAH SJ, WITTELES RM, et al. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019;74(3):285–295.
- 25. GAMEZ J, SALVADO M, REIG N, SUNE P, CASASNOVAS C, ROJAS-GARCIA R, et al. Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study(.). Amyloid. 2019;26(2):74–84.
- 26. SUHR O, GROGAN M, MARTINS DA SILVA A. Neurological and cardiac improvements with PRX004 in amyloidosis patients: results of a phase 1 study, 2021 emerging science abstracts. 2021 AAN annual meeting abstracts. Neurology. 2021;96(22): e2783–e2788.